Kite Pharma (KITE) Posts Q4 Loss of 85c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies Reiterates Buy on Kite Pharma (KITE) Following a Mixed 4Q - PT to $75
March 1, 2016 9:31 AM ESTJefferies maintained a Buy rating on Kite Pharma (NASDAQ: KITE), and cut the price target to $75.00 (from $92.00), following the company's 4Q earnings conference call. KITE reported Q4 revenues of $4.9M, coming in ahead of Jefferies' estimate of $4.4M. GAAP EPS of ($0.85) also beat estimates... More
Citi Starts Kite Pharma (KITE) at Buy
February 25, 2016 8:25 AM ESTCiti initiatesd coverage on Kite Pharma (NASDAQ: KITE) with a Buy rating and a price target of $67.00.
For an analyst ratings summary and ratings history on Kite Pharma click here. For more ratings news on Kite Pharma click here.
Shares of Kite Pharma closed at $44.97 yesterday.
... More